Comment on: pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis

Grimes, Tamasine; Breslin, Niall; Deasy, Evelyn; Moloney, E; O'Byrne, John C.; Wall, Catherine; Delaney, Tim

doi:10.1111/jcpt.12452

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ample evidence suggests that pharmacist medication reconciliation or a discharge medication report can reduce the number of medication errors after discharge . The evidence regarding the clinical consequences of the reduced number of medication errors, however, is equivocal.…”

Section: Introductionmentioning

confidence: 99%

“…13 Ample evidence suggests that pharmacist medication reconciliation or a discharge medication report can reduce the number of medication errors after discharge. [14][15][16][17][18][19] The evidence regarding the clinical consequences of the reduced number of medication errors, however, is equivocal. Most of these studies had fairly simple single-component interventions and were thereby not likely to be successful in terms of preventing hard clinical outcomes.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission

et al. 2018

View full text Add to dashboard Cite

Hospital readmissions are common among patients receiving multiple medications, with considerable costs to the patients and society.OBJECTIVE To determine whether a multifaceted pharmacist intervention based on medication review, patient interview, and follow-up can reduce the number of readmissions and emergency department (ED) visits. DESIGN, SETTING, AND PARTICIPANTSThis randomized clinical multicenter study (Odense Pharmacist Trial Investigating Medication Interventions at Sector Transfer [OPTIMIST]) enrolled patients from September 1, 2013, through April 23, 2015, with a follow-up of 6 months completed on October 31, 2015. Consecutive medical patients in an acute admission ward who were 18 years or older and who used 5 or more medications were invited to participate. Of 1873 patients invited to participate, 1499 (80.0%) accepted. The medication review and patient interview were conducted in the hospital and followed up in collaboration with primary care. Analysis was based on intention to treat. INTERVENTIONSThe patients were randomized into 3 groups receiving usual care (no intervention), a basic intervention (medication review), and an extended intervention (medication review, 3 motivational interviews, and follow-up with the primary care physician, pharmacy, and nursing home). MAIN OUTCOMES AND MEASURESThe prespecified primary outcomes were readmission within 30 or 180 days and ED visits within 180 days. The primary composite end point was readmission or an ED visit within 180 days. Secondary outcomes were drug-related readmissions within 30 and 180 days after inclusion, and all-cause mortality and drug-related mortality.RESULTS A total of 1467 patients (679 men [46.3%] and 788 women [53.7%]; median age, 72 years; interquartile range, 63-80 years) were part of the primary analysis, including 498 randomized to usual care, 493 randomized to the basic intervention, and 476 randomized to the extended intervention. The extended intervention had a significant effect on the numbers of patients who were readmitted within 30 days (hazard ratio [HR], 0.62; 95% CI, 0.46-0.84) or within 180 days (HR, 0.75; 95% CI, 0.62-0.90) after inclusion and on the number of patients who experienced the primary composite end point (HR, 0.77; 95% CI, 0.64-0.93). The study showed a nonsignificant reduction in drug-related readmissions within 30 days (HR, 0.65; 95% CI, 0.39-1.09) and within 180 days (HR, 0.80; 95% CI, 0.59-1.08) after inclusion and in deaths (HR, 0.83; 95% CI,. The number needed to treat to achieve the primary composite outcome for the extended intervention (vs usual care) was 12.CONCLUSIONS AND RELEVANCE A multifaceted clinical pharmacist intervention may reduce the number of ED visits and hospital readmissions.TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT03079375

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies have shown that pharmacists’ medication adjustment or discharge medication reports can reduce the number of medication errors after discharge. [ 15 , 16 ] Clinical pharmacists can effectively identify, prevent and solve clinically important DRPs. [ 17 , 18 ] Since clinical pharmacists participate more in clinical treatment, drug-drug interaction decreases and patients’ understanding of drugs is improving, thereby effectively preventing and reducing DRPs.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effect of pharmaceutical care during inpatient treatment in a department of neurology: A retrospective study

Xiao

et al. 2022

Medicine

View full text Add to dashboard Cite

Common drug-related problems during neurology inpatient treatment can affect expected health results. Some interventions need to be implemented to reduce DRPs. To explore the effect of care from clinical pharmacists during inpatient treatment. Inpatients treated in the department of neurology in the Second Hospital of Shanxi Medical University between January 1 to December 31, 2019, were retrospectively included. Those who received care from the clinical pharmacist service were assigned to the pharma-care group while the other patients were assigned to the control group. From the perspective of drugs, the two groups were compared in terms of types, antimicrobial use, and key monitoring of drug use. From the perspective of patients, the two groups were compared in terms of length of stay, hospital cost, drug cost and proportion. Propensity score matching was used to balance the baseline characteristics. A total of 2684 patients were included 554 in the pharma-care group and 2130 in the control group with a median of 9 days (range, 3–30 days) hospital stay. The groups showed no significant difference in age or gender. Length of stay, the proportion of drug cost, number of adverse events, cost of antibacterial agents, use of a single antibacterial agent, and use of three or more different antibacterial agents were similar between the groups. Medicine expenses cost more in the pharma-care group. The cost and types of intensive monitoring drugs were similar, but Defined Daily Doses were lower in the control group. While clinical pharmacists may play a positive role in the pharmaceutical care of inpatients, in this study the benefits were not obvious. This may be because of the small number of clinical pharmacists in the department of neurology with narrow coverage.

show abstract

Comment on: pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis

Cited by 2 publications

References 7 publications

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission

Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission

Evaluation of the effect of pharmaceutical care during inpatient treatment in a department of neurology: A retrospective study

Contact Info

Product

Resources

About